ABSTRACT
Apolipoprotein A5 (ApoA5) is a newly discovered apolipoprotein which is closely associated with high-density lipoprotein (HDL) remodeling. Clinically it demonstrates potent triglyceride reducing effect. Recent studies have found that ApoA5 can increase cholesteroal reverse transportation and HDL function by remodeling HDL, and it can also influence the progression of atherosclerosis in the different ways, showing a potential anti-atherosclerosis effect. Here we briefly review the characteristics of ApoA5 and its potential protective effect against atherosclerosis.
ABSTRACT
Sodium glucose co-transporter (SGLT) is one of the transporters responsible for the resorpcion of glucose, and inhibition of its activity can decrease the resorption of glucose. Human SGLT is mainly composed of SGLT1 and SGLT2. Due to the specific distribution and the high efficiency of SGLT2, SGLT2 inhibitor is a potential new strategy for treatment diabetes. Abundant animal experiments and clinical trails have found that SGLT2 inhibitor can greatly lower the blood glucose and help to lose weights. However, the current researches about SGLT2 inhibitor are still very limited both in depth and in broadness; problems concerning the safety, efficacy and indication of SGLT2 inhibitor still need to be further studied.